Sutro Biopharma
STRO· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -37.1% in FY2025
Jane Chung, R.Ph. is the CEO of Sutro Biopharma and was paid $1.6M in FY2025 (Dec), up 9%.
Pay$100 in the stock at the end of FY22 → $14
Executives4
See all- 1William J. NewellFormer Chief Executive OfficerFY2025
- 2Jane Chung, R.Ph.Chief Executive OfficerFY2025
- 3Hans-Peter Gerber, Ph.D.Chief Scientific OfficerFY2025
- 4Gregory ChowChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allSutro Biopharma paid its 4 named executives $5.0M in total in FY2025 (Dec). CEO Jane Chung, R.Ph. was paid $1.6M of that.
| Name | |||
|---|---|---|---|
| William J. NewellFormer Chief Executive Officer | |||
| Jane Chung, R.Ph.Chief Executive Officer | |||
| Hans-Peter Gerber, Ph.D.Chief Scientific Officer | |||
| Gregory ChowChief Financial Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See allThe comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board3
See all- Michael DybbsDirector · 7 yr on the boardIndependentScience and Technology—Paid as an executive
- Jon WiggintonDirector · 5 yr on the boardIndependentCompensation, Science and Technology (Chair)—Paid as an executive
- Heidi HunterDirector · 4 yr on the boardIndependentAudit, Science and Technology—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 22, 2026 | FY2025 |
| Annual report | 10-K | Mar 23, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 25, 2025 | FY2024 |
| Annual report | 10-K | Mar 13, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 25, 2024 | FY2023 |